Large Molecule Patents

Humira is a drug owned by Abbvie Inc.. It is protect by 66 US patents. Given below is the list of those patents along with their expiration dates.

Patent Number Company Patent Title Patent Expiry Activity Alert
US9550826 ABBVIE INC. Glycoengineered binding protein compositions
Nov, 2034

(10 years from now)

Active
US9499614 ABBVIE INC. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
Mar, 2034

(9 years from now)

Active
US9150645 ABBVIE INC. Cell culture methods to reduce acidic species
May, 2033

(8 years from now)

Active
US9266949 ABBVIE INC. Low acidic species compositions and methods for producing and using the same
May, 2033

(8 years from now)

Active
US9315574 ABBVIE INC. Low acidic species compositions and methods for producing and using the same
Apr, 2033

(8 years from now)

Active
US9085618 ABBVIE INC. Low acidic species compositions and methods for producing and using the same
Mar, 2033

(8 years from now)

Active
US9181337 ABBVIE INC. Modulated lysine variant species compositions and methods for producing and using the same
Mar, 2033

(8 years from now)

Active
US9181572 ABBVIE INC. Methods to modulate lysine variant distribution
Mar, 2033

(8 years from now)

Active
US9290568 ABBVIE INC. Methods to control protein heterogeneity
Mar, 2033

(8 years from now)

Active
US9334319 ABBVIE INC. Low acidic species compositions
Mar, 2033

(8 years from now)

Active
US9346879 ABBVIE INC. Protein purification methods to reduce acidic species
Mar, 2033

(8 years from now)

Active
US9359434 ABBVIE INC. Cell culture methods to reduce acidic species
Mar, 2033

(8 years from now)

Active
US9499616 ABBVIE INC. Modulated lysine variant species compositions and methods for producing and using the same
Mar, 2033

(8 years from now)

Active
US9708400 ABBVIE INC. Methods to modulate lysine variant distribution
Mar, 2033

(8 years from now)

Active
US9062106 ABBVIE INC. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Apr, 2032

(7 years from now)

Active
US9090688 ABBVIE INC. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Apr, 2032

(7 years from now)

Active
US9505834 ABBVIE INC. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Apr, 2032

(7 years from now)

Active
US9522953 ABBVIE INC. Low acidic species compositions and methods for producing and using the same
Apr, 2032

(7 years from now)

Active
US9683033 ABBVIE INC. Cell culture methods to reduce acidic species
Apr, 2032

(7 years from now)

Active
US9957318 ABBVIE INC. Protein purification methods to reduce acidic species
Apr, 2032

(7 years from now)

Active
US8708968 ABBVIE INC. Removal of needle shields from syringes and automatic injection devices
Jan, 2032

(7 years from now)

Active
US9339610 ABBVIE INC. Removal of needle shield from syringes and automatic injection devices
Jan, 2032

(7 years from now)

Active
US9624295 ABBVIE INC. Uses and compositions for treatment of psoriatic arthritis
Mar, 2031

(6 years from now)

Active
US8999337 ABBVIE INC. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
Feb, 2031

(6 years from now)

Active
US8420081 ABBVIE INC. Antibody formulations and methods of making same
Jan, 2030

(5 years from now)

Active
US11167030 ABBVIE INC. Protein formulations and methods of making same
Nov, 2028

(4 years from now)

Active
US11191834 ABBVIE INC. Protein formulations and methods of making same
Nov, 2028

(4 years from now)

Active
US9085619 ABBVIE INC. Anti-TNF antibody formulations
Nov, 2028

(4 years from now)

Active
US9284370 ABBVIE INC. Methods for treating juvenile idiopathic arthritis
Jun, 2028

(3 years from now)

Active
US9669093 ABBVIE INC. Methods for treating juvenile idiopathic arthritis
Jun, 2028

(3 years from now)

Active
US8889136 ABBVIE INC. Multiple-variable dose regimen for treating TNFα-related disorders
Oct, 2027

(2 years from now)

Active
US8663945 ABBVIE INC. Methods of producing anti-TNF-alpha antibodies in mammalian cell culture
Sep, 2027

(2 years from now)

Active
US8906646 ABBVIE INC. Fed-batch method of making human anti-TNF-alpha antibody
Sep, 2027

(2 years from now)

Active
US8911964 ABBVIE INC. Fed-batch method of making human anti-TNF-alpha antibody
Sep, 2027

(2 years from now)

Active
US9090867 ABBVIE INC. Fed-batch method of making anti-TNF-alpha antibody
Sep, 2027

(2 years from now)

Active
US9234032 ABBVIE INC. Fed-batch methods for producing adalimumab
Sep, 2027

(2 years from now)

Active
US9284371 ABBVIE INC. Methods of producing adalimumab
Sep, 2027

(2 years from now)

Active
US8715664 ABBVIE INC. Use of human TNFα antibodies for treatment of erosive polyarthritis
Jul, 2027

(2 years from now)

Active
US8926975 ABBVIE INC. Method of treating ankylosing spondylitis
Jun, 2027

(2 years from now)

Active
US11083792 ABBVIE INC. Purified antibody composition
Apr, 2027

(2 years from now)

Active
US8231876 ABBVIE INC. Purified antibody composition
Apr, 2027

(2 years from now)

Active
US8883156 ABBVIE INC. Purified antibody composition
Apr, 2027

(2 years from now)

Active
US8895009 ABBVIE INC. Purified antibody composition
Apr, 2027

(2 years from now)

Active
US8906372 ABBVIE INC. Purified antibody composition
Apr, 2027

(2 years from now)

Active
US8916153 ABBVIE INC. Purified antibody composition
Apr, 2027

(2 years from now)

Active
US9096666 ABBVIE INC. Purified antibody composition
Apr, 2027

(2 years from now)

Active
US9102723 ABBVIE INC. Purified antibody composition
Apr, 2027

(2 years from now)

Active
US9273132 ABBVIE INC. Purified antibody composition
Apr, 2027

(2 years from now)

Active
US9328165 ABBVIE INC. Purified antibody composition
Apr, 2027

(2 years from now)

Active
US9913902 ABBVIE INC. Purified antibody composition
Apr, 2027

(2 years from now)

Active
US8808700 ABBVIE INC. Use of TNF alpha inhibitor for treatment of erosive polyarthritis
May, 2026

(1 year, 6 months from now)

Active
US8961973 ABBVIE INC. Multiple-variable dose regimen for treating TNFα-related disorders
Apr, 2025

(5 months from now)

Active
US8961974 ABBVIE INC. Multiple-variable dose regimen for treating TNFα-related disorders
Apr, 2025

(5 months from now)

Active
US8986693 ABBVIE INC. Use of TNFα inhibitor for treatment of psoriasis
Apr, 2025

(5 months from now)

Active
US9061005 ABBVIE INC. Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
Apr, 2025

(5 months from now)

Active
US9187559 ABBVIE INC. Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
Apr, 2025

(5 months from now)

Active
US9512216 ABBVIE INC. Use of TNFα inhibitor
Apr, 2025

(5 months from now)

Active
US8906373 ABBVIE INC. Use of TNF-alpha inhibitor for treatment of psoriasis
Jul, 2023

(1 year, 2 months ago)

Expired
US9067992 ABBVIE INC. Use of TNFα inhibitor for treatment of psoriatic arthritis
Jul, 2023

(1 year, 2 months ago)

Expired
US9085620 ABBVIE INC. Use of TNFα inhibitor for treatment of psoriatic arthritis
Jul, 2023

(1 year, 2 months ago)

Expired
US9090689 ABBVIE INC. Use of TNFα inhibitor for treatment of psoriasis
Jul, 2023

(1 year, 2 months ago)

Expired
US6805686 ABBVIE INC. Autoinjector with extendable needle protector shroud
May, 2023

(1 year, 5 months ago)

Expired
US8911737 ABBVIE INC. Methods of administering anti-TNFα antibodies
Jun, 2022

(2 years ago)

Expired
US8974790 ABBVIE INC. Methods of administering anti-TNFα antibodies
Jun, 2022

(2 years ago)

Expired
US8992926 ABBVIE INC. Methods of administering anti-TNFα antibodies
Jun, 2022

(2 years ago)

Expired
US9546212 ABBVIE INC. Methods of administering anti-TNFα antibodies
Jun, 2022

(2 years ago)

Expired


Humira's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


About Humira

Active Ingredients:

Humira contains Adalimumab as an active ingredient

Approval Date:

Humira was first approved for market use on 31 Dec, 2002.

Dosage:

Humira is available in 7 strengths and the following dosage forms are - Injection form for Subcutaneous use, Injection form for Subcutaneous use.

Strength Dosage Form Availability Application Pathway
40MG/0.8ML Injection Rx Subcutaneous
80MG/0.8ML Injection Rx Subcutaneous
80MG/0.8ML Injection Rx Subcutaneous
20MG/0.4ML Injection Rx Subcutaneous
40MG/0.4ML Injection Rx Subcutaneous
20MG/0.2ML Injection Rx Subcutaneous
20MG/0.4ML Injection Disc Subcutaneous
40MG/0.4ML Injection Rx Subcutaneous
20MG/0.2ML Injection Rx Subcutaneous
20MG/0.4ML Injection Disc Subcutaneous
20MG/0.2ML Injection Rx Subcutaneous
10MG/0.1ML Injection Rx Subcutaneous
80MG/0.8ML Injection Rx Subcutaneous
40MG/0.4ML Injection Rx Subcutaneous
80MG/0.8ML Injection Rx Subcutaneous
10MG/0.2ML Injection Disc Subcutaneous
40MG/0.8ML Injection Rx Subcutaneous
10MG/0.1ML Injection Rx Subcutaneous
10MG/0.2ML Injection Disc Subcutaneous
10MG/0.1ML Injection Rx Subcutaneous
40MG/0.4ML Injection Rx Subcutaneous
20MG/0.4ML Injection Disc Subcutaneous
10MG/0.2ML Injection Rx Subcutaneous
40MG/0.8ML Injection Rx Subcutaneous
10MG/0.2ML Injection Disc Subcutaneous
40MG/0.8ML Injection Rx Subcutaneous